☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
46-4838035 | |||||||
(State or other jurisdiction of incorporation)
|
(I.R.S. Employer Identification No.)
|
|||||||
30 Hudson Street, Floor 33 | ||||||||
Jersey City
|
New Jersey
|
07302 | ||||||
(Address of principal executive offices) (zip code)
|
Not Applicable
|
||||||||
(Former name, former address and former fiscal year, if changed since last report.)
|
Securities registered pursuant to Section 12(b) of the Act:
|
||||||||
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||||||
Common Stock ($0.01 par value)
|
OGN
|
New York Stock Exchange
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
||||||||
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☐
|
||||||||
Emerging growth company
|
☐
|
Page No. | ||||||||
PART I | ||||||||
Item 1. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
PART II | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 6. | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Sales | $ | 1,600 | $ | 1,613 | $ | 4,701 | $ | 4,919 | |||||||||||||||
Costs, Expenses and Other | |||||||||||||||||||||||
Cost of sales | 609 | 535 | 1,783 | 1,533 | |||||||||||||||||||
Selling, general and administrative | 388 | 321 | 1,186 | 922 | |||||||||||||||||||
Research and development | 111 | 54 | 254 | 150 | |||||||||||||||||||
Restructuring costs | 1 | 12 | 3 | 43 | |||||||||||||||||||
Other (income) expense, net | 102 | 10 | 182 | 44 | |||||||||||||||||||
1,211 | 932 | 3,408 | 2,692 | ||||||||||||||||||||
Income From Continuing Operations Before Income Taxes | 389 | 681 | 1,293 | 2,227 | |||||||||||||||||||
Taxes on Income | 66 | 121 | 144 | 347 | |||||||||||||||||||
Net Income From Continuing Operations | 323 | 560 | 1,149 | 1,880 | |||||||||||||||||||
Loss From Discontinued Operations - Net of Tax | — | (13) | — | (88) | |||||||||||||||||||
Net Income | $ | 323 | $ | 547 | $ | 1,149 | $ | 1,792 | |||||||||||||||
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Basic: | |||||||||||||||||||||||
Continuing operations | $ | 1.27 | $ | 2.21 | $ | 4.53 | $ | 7.42 | |||||||||||||||
Discontinued operations | — | (0.05) | — | (0.35) | |||||||||||||||||||
Net Earnings per Share Attributable to Organon & Co. Stockholders | $ | 1.27 | $ | 2.16 | $ | 4.53 | $ | 7.07 | |||||||||||||||
Earnings (Loss) per Share Attributable to Organon & Co. Stockholders - Diluted: | |||||||||||||||||||||||
Continuing operations | $ | 1.27 | $ | 2.21 | $ | 4.52 | $ | 7.42 | |||||||||||||||
Discontinued operations | — | (0.05) | — | (0.35) | |||||||||||||||||||
Net Earnings per Share Attributable to Organon & Co. Stockholders | $ | 1.27 | $ | 2.16 | $ | 4.52 | $ | 7.07 | |||||||||||||||
Weighted Average Shares Outstanding: | |||||||||||||||||||||||
Basic | 253,534,000 | 253,516,000 | 253,530,000 | 253,516,000 | |||||||||||||||||||
Diluted | 254,172,000 | 253,516,000 | 254,011,000 | 253,516,000 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Net Income | $ | 323 | $ | 547 | $ | 1,149 | $ | 1,792 | |||||||||||||||
Other Comprehensive Income (Loss), Net of Taxes: | |||||||||||||||||||||||
Benefit plan net (loss) gain and prior service credit, net of amortization
|
(3) | 4 | (11) | 15 | |||||||||||||||||||
Cumulative translation adjustment
|
(23) | 40 | 129 | (93) | |||||||||||||||||||
(26) | 44 | 118 | (78) | ||||||||||||||||||||
Comprehensive Income | $ | 297 | $ | 591 | $ | 1,267 | $ | 1,714 |
September 30, 2021 | December 31, 2020 | ||||||||||
Assets | |||||||||||
Current Assets | |||||||||||
Cash and cash equivalents | $ | 1,008 | $ | 12 | |||||||
Accounts receivable (net of allowance for doubtful accounts of $8 in
2021 and $18 in 2020)
|
1,498 | 1,038 | |||||||||
Inventories (excludes inventories of $60 in 2021 and $127 in 2020 classified in Other Assets)
|
918 | 913 | |||||||||
Other current assets | 905 | 930 | |||||||||
Current assets of discontinued operations | — | 674 | |||||||||
Total current assets | 4,329 | 3,567 | |||||||||
Property, plant and equipment, net | 967 | 984 | |||||||||
Goodwill | 4,603 | 4,603 | |||||||||
Other intangibles, net | 683 | 503 | |||||||||
Other assets | 753 | 361 | |||||||||
Noncurrent assets of discontinued operations | — | 91 | |||||||||
$ | 11,335 | $ | 10,109 | ||||||||
Liabilities and Equity | |||||||||||
Current Liabilities | |||||||||||
Current portion of long-term debt | $ | 39 | $ | — | |||||||
Trade accounts payable | 1,673 | 259 | |||||||||
Accrued and other current liabilities | 1,082 | 659 | |||||||||
Due to related party | — | 1,339 | |||||||||
Income taxes payable | 335 | 288 | |||||||||
Current liabilities of discontinued operations | — | 128 | |||||||||
Total current liabilities | 3,129 | 2,673 | |||||||||
Long-term debt | 9,259 | — | |||||||||
Deferred income taxes | 59 | 128 | |||||||||
Other noncurrent liabilities | 506 | 1,739 | |||||||||
Noncurrent liabilities of discontinued operations | — | 83 | |||||||||
Commitments and Contingencies | |||||||||||
Organon & Co. Equity | |||||||||||
Common stock, $0.01 par value
Authorized - 500,000,000
Issued and outstanding - 253,545,051
|
3 | — | |||||||||
Additional paid-in capital | — | — | |||||||||
Accumulated deficit | (1,128) | — | |||||||||
Net investment from Merck & Co., Inc. | — | 6,108 | |||||||||
Accumulated other comprehensive loss | (493) | (622) | |||||||||
Total Equity | (1,618) | 5,486 | |||||||||
$ | 11,335 | $ | 10,109 |
Common Stock | Additional Paid-In Capital | Accumulated Deficit | Net Investment from Merck & Co., Inc. |
Accumulated
Other Comprehensive (Loss) Income |
Total | ||||||||||||||||||||||||||||||||||||
Shares | Par Value | ||||||||||||||||||||||||||||||||||||||||
Balance at July 1, 2020
|
— | $ | — | $ | — | $ | — | $ | 8,041 | $ | (1,036) | $ | 7,005 | ||||||||||||||||||||||||||||
Net income attributable to Organon & Co. | — | — | — | — | 547 | — | 547 | ||||||||||||||||||||||||||||||||||
Other comprehensive income, net of taxes | — | — | — | — | — | 44 | 44 | ||||||||||||||||||||||||||||||||||
Net transfers to Merck & Co., Inc.
|
— | — | — | — | (261) | — | (261) | ||||||||||||||||||||||||||||||||||
Balance at September 30, 2020 | — | $ | — | $ | — | $ | — | $ | 8,327 | $ | (992) | $ | 7,335 | ||||||||||||||||||||||||||||
Balance at July 1, 2021
|
253,516,000 | $ | 3 | $ | — | $ | (1,473) | $ | — | $ | (464) | $ | (1,934) | ||||||||||||||||||||||||||||
Net income attributable to Organon | — | — | — | 323 | — | — | 323 | ||||||||||||||||||||||||||||||||||
Other comprehensive income, net of taxes | — | — | — | — | — | (26) | (26) | ||||||||||||||||||||||||||||||||||
Cash dividends declared on common stock | — | — | — | (74) | — | — | (74) | ||||||||||||||||||||||||||||||||||
Net transfers from Merck & Co., Inc., including Separation Adjustments | — | — | — | 81 | — | (3) | 78 | ||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | 29,051 | — | — | 15 | — | — | 15 | ||||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | 253,545,051 | $ | 3 | $ | — | $ | (1,128) | $ | — | $ | (493) | $ | (1,618) |
Common Stock | Additional Paid-In Capital | Accumulated Deficit | Net Investment from Merck & Co., Inc. |
Accumulated
Other Comprehensive (Loss) Income |
Total | ||||||||||||||||||||||||||||||||||||
Shares | Par Value | ||||||||||||||||||||||||||||||||||||||||
Balance at January 1, 2020
|
— | $ | — | $ | — | $ | — | $ | 7,949 | $ | (914) | $ | 7,035 | ||||||||||||||||||||||||||||
Net income attributable to Organon & Co. | — | — | — | — | 1,792 | — | 1,792 | ||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of taxes | — | — | — | — | — | (78) | (78) | ||||||||||||||||||||||||||||||||||
Net transfers to Merck & Co., Inc.
|
— | — | — | — | (1,414) | — | (1,414) | ||||||||||||||||||||||||||||||||||
Balance at September 30, 2020 | — | $ | — | $ | — | $ | — | $ | 8,327 | $ | (992) | $ | 7,335 | ||||||||||||||||||||||||||||
Balance at January 1, 2021
|
— | $ | — | $ | — | $ | — | $ | 6,108 | $ | (622) | $ | 5,486 | ||||||||||||||||||||||||||||
Net income attributable to Organon | — | — | — | 419 | 730 | — | 1,149 | ||||||||||||||||||||||||||||||||||
Other comprehensive income, net of taxes | — | — | — | — | — | 118 | 118 | ||||||||||||||||||||||||||||||||||
Cash dividends declared on common stock | — | — | — | (74) | — | — | (74) | ||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | 29,051 | — | — | 23 | — | — | 23 | ||||||||||||||||||||||||||||||||||
Net transfers from Merck & Co., Inc., including Separation Adjustments | — | — | — | 81 | 588 | 11 | 680 | ||||||||||||||||||||||||||||||||||
Net consideration paid to Merck & Co. Inc. in connection with Separation | — | — | — | (9,000) | — | (9,000) | |||||||||||||||||||||||||||||||||||
Issuance of common stock in connection with the Separation and reclassification of Net investment from Merck & Co., inc.
|
253,516,000 | 3 | — | (1,577) | 1,574 | — | — | ||||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | 253,545,051 | $ | 3 | $ | — | $ | (1,128) | $ | — | $ | (493) | $ | (1,618) |
Nine Months Ended September 30, | |||||||||||
2021 | 2020 | ||||||||||
Cash Flows from Operating Activities | |||||||||||
Net income from continuing operations | $ | 1,149 | $ | 1,880 | |||||||
Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities: | |||||||||||
Depreciation | 64 | 42 | |||||||||
Amortization | 69 | 65 | |||||||||
Acquired in-process research & development | 25 | — | |||||||||
Deferred income taxes | (212) | 18 | |||||||||
Stock-based compensation | 44 | 32 | |||||||||
Unrealized foreign exchange loss | 37 | — | |||||||||
Other | 7 | — | |||||||||
Net changes in assets and liabilities | |||||||||||
Accounts receivable | (376) | (127) | |||||||||
Inventories | (90) | 1 | |||||||||
Other current assets | 177 | 120 | |||||||||
Trade accounts payable | 944 | 11 | |||||||||
Accrued and other current liabilities | 386 | (69) | |||||||||
Due from/due to related party | (164) | — | |||||||||
Income taxes payable | 7 | (148) | |||||||||
Other | 46 | (25) | |||||||||
Net Cash Flows Provided by Operating Activities from Continuing Operations | 2,113 | 1,800 | |||||||||
Cash Flows from Investing Activities | |||||||||||
Capital expenditures | (133) | (134) | |||||||||
Proceeds from sale of property, plant and equipment | 2 | 3 | |||||||||
Acquired in-process research & development | (25) | — | |||||||||
Purchase of intangible asset - Alydia Health, net of cash acquired | (192) | — | |||||||||
Net Cash Flows Used in Investing Activities from Continuing Operations | (348) | (131) | |||||||||
Cash Flows from Financing Activities | |||||||||||
Proceeds from issuance of long-term debt | 9,470 | — | |||||||||
Repayments of debt | (10) | — | |||||||||
Payment of long-term debt issuance costs | (118) | — | |||||||||
Repayments of short-term borrowings from Merck & Co., Inc., net | (1,512) | — | |||||||||
Net consideration paid to Merck & Co., Inc., in connection with the Separation | (9,000) | — | |||||||||
Net transfers from (to) Merck & Co., Inc. | 454 | (1,669) | |||||||||
Dividend payments | (74) | — | |||||||||
Net Cash Flows Used in Financing Activities from Continuing Operations | (790) | (1,669) | |||||||||
Discontinued Operations | |||||||||||
Net Cash Provided by (Used in) Operating Activities | 298 | (43) | |||||||||
Net Cash Used in Investing Activities | — | (9) | |||||||||
Net Cash (Used in) Provided by Financing Activities | (356) | 171 | |||||||||
Net Cash Flows (Used in) Provided by Discontinued Operations | (58) | 119 | |||||||||
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Continuing Operations | 21 | — | |||||||||
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Discontinued Operations | — | (57) | |||||||||
Net Increase in Cash and Cash Equivalents | 938 | 62 | |||||||||
Cash and Cash Equivalents, Beginning of Period | 12 | — | |||||||||
Cash and Cash Equivalents of Discontinued Operations, Beginning of Period | 58 | 319 | |||||||||
Total Cash and Cash Equivalents, End of Period | 1,008 | 381 | |||||||||
Less: Cash and Cash Equivalents of Discontinued Operations, End of Period | — | 381 | |||||||||
Cash and Cash Equivalents, End of Period | $ | 1,008 | $ | — |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Sales | $ | 139 | $ | 99 | $ | 305 | $ | 227 | |||||||||||||||
Cost of sales | 83 | 65 | 183 | 144 | |||||||||||||||||||
Selling, general and administrative | 19 | 25 | 50 | 62 |
($ in millions) | September 30, 2021 | December 31, 2020 | |||||||||
Receivables from Samsung included in Other current assets
|
$ | 12 | $ | 52 | |||||||
Payables to Samsung included in Trade accounts payable
|
36 | 13 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Allocated net (gains) loss in Sales
|
$ | — | $ | 6 | $ | (56) | $ | (12) | |||||||||||||||
Net (gains) loss in Other (income) expense, net(1)
|
(3) | 82 | 29 | 97 | |||||||||||||||||||
Foreign exchange (gains) loss in Other (income) expense, net(1)
|
4 | (64) | (23) | (45) |
($ in millions) | September 30, 2021 | December 31, 2020 | |||||||||
Finished goods | $ | 359 | $ | 351 | |||||||
Raw materials
|
78 | 35 | |||||||||
Work in process | 509 | 595 | |||||||||
Supplies | 38 | 60 | |||||||||
Total (approximates current cost) | $ | 984 | $ | 1,041 | |||||||
Decrease to LIFO costs | (6) | (1) | |||||||||
$ | 978 | $ | 1,040 | ||||||||
Recognized as: | |||||||||||
Inventories | $ | 918 | $ | 913 | |||||||
Other assets | 60 | 127 |
($ in millions) | September 30, 2021 | December 31, 2020 | |||||||||
Land | $ | 14 | $ | 14 | |||||||
Building | 600 | 647 | |||||||||
Machinery, equipment and office furnishings | 913 | 787 | |||||||||
Construction in progress | 317 | 356 | |||||||||
Less: accumulated depreciation | (877) | (820) | |||||||||
Property, Plant and Equipment, net | $ | 967 | $ | 984 |
($ in millions) | September 30, 2021 | ||||
Term Loan B Facility: | |||||
LIBOR plus 300 bps term loan due 2028
|
$ | 2,993 | |||
LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)
|
874 | ||||
4.125% secured notes due 2028
|
2,100 | ||||
2.875% euro-denominated secured notes due 2028 (€1.25 billion)
|
1,461 | ||||
5.125% notes due 2031
|
2,000 | ||||
Other (discounts and debt issuance costs) | (130) | ||||
Total principal long-term debt | $ | 9,298 | |||
Less: Current portion of long-term debt | 39 | ||||
Total Long-term debt, net of current portion | $ | 9,259 |
($ in millions) | September 30, 2021 | December 31, 2020 | |||||||||
Assets | |||||||||||
Other Assets | $ | 288 | $ | 31 | |||||||
Liabilities | |||||||||||
Accrued and other current liabilities | 67 | 8 | |||||||||
Other Noncurrent Liabilities | 221 | 23 | |||||||||
$ | 288 | $ | 31 | ||||||||
Weighted-average remaining lease term (years) | 5.3 | 4.0 | |||||||||
Weighted-average discount rate | 3.2% | 1.9% |
2021 (excluding the first nine months of 2021)
|
$ | 19 | |||
2022 | 75 | ||||
2023 | 70 | ||||
2024 | 53 | ||||
2025 | 36 | ||||
Thereafter | 61 | ||||
Total lease payments | $ | 314 | |||
Less: Imputed interest | 26 | ||||
$ | 288 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Stock-based compensation expense | $ | 15 | $ | 11 | $ | 44 | $ | 32 | |||||||||||||||
Income tax benefits | 3 | 2 | 9 | 7 |
Three Months Ended September 30, 2021 | |||||
Expected dividend yield | 3.22 | % | |||
Risk-free interest rate | 0.92 | % | |||
Expected volatility | 45.80 | % | |||
Expected life (years) | 5.89 |
Equity Awards Vested and Expected to Vest | Equity Awards That are Exercisable | ||||||||||||||||||||||||||||||||||||||||||||||
(shares in thousands; aggregate intrinsic value in millions) | Awards | Weighted Average Exercise Price | Aggregate Intrinsic Value | Remaining Term | Awards | Weighted Average Exercise Price | Aggregate Intrinsic Value | Remaining Term | |||||||||||||||||||||||||||||||||||||||
Stock Options | 4,162 | $ | 34.39 | $ | 5 | 8.29 | 1,454 | $ | 30.66 | $ | 5 | 5.90 | |||||||||||||||||||||||||||||||||||
Restricted Share Units | 3,016 | — | 108 | 2.18 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
Performance Share Units | 201 | — | 8 | 2.88 | — | — | — | — |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Exchange (gains) losses | $ | 1 | $ | 18 | $ | 6 | $ | 52 | |||||||||||||||
Interest expense | 98 | — | 160 | — | |||||||||||||||||||
Other, net | 3 | (8) | 16 | (8) | |||||||||||||||||||
$ | 102 | $ | 10 | $ | 182 | $ | 44 |
($ in millions) |
Employee
Benefit Plans |
Cumulative
Translation Adjustment |
Accumulated Other
Comprehensive Income (Loss) |
||||||||||||||
Balance at July 1, 2020, net of taxes
|
$ | (343) | $ | (693) | $ | (1,036) | |||||||||||
Other comprehensive income (loss), pretax | 4 | 40 | 44 | ||||||||||||||
Tax | — | — | — | ||||||||||||||
Other comprehensive income (loss), net of taxes | 4 | 40 | 44 | ||||||||||||||
Balance at September 30, 2020, net of taxes
|
$ | (339) | $ | (653) | $ | (992) | |||||||||||
Balance at July 1, 2021, net of taxes
|
$ | (26) | $ | (438) | $ | (464) | |||||||||||
Other comprehensive income (loss), pretax | (3) | (23) | (26) | ||||||||||||||
Tax | — | — | — | ||||||||||||||
Other comprehensive income (loss), net of taxes | (3) | (23) | (26) | ||||||||||||||
Transfer of benefit plans from Merck affiliates | (3) | — | (3) | ||||||||||||||
Balance at September 30, 2021, net of taxes
|
$ | (32) | $ | (461) | $ | (493) |
($ in millions) |
Employee
Benefit Plans |
Cumulative
Translation Adjustment |
Accumulated Other
Comprehensive Income (Loss) |
||||||||||||||
Balance at January 1, 2020, net of taxes
|
$ | (354) | $ | (560) | $ | (914) | |||||||||||
Other comprehensive income (loss), pretax | 18 | (93) | (75) | ||||||||||||||
Tax | (3) | — | (3) | ||||||||||||||
Other comprehensive income (loss), net of taxes | 15 | (93) | (78) | ||||||||||||||
Balance at September 30, 2020, net of taxes
|
$ | (339) | $ | (653) | $ | (992) | |||||||||||
Balance at January 1, 2021, net of taxes
|
$ | (32) | $ | (590) | $ | (622) | |||||||||||
Other comprehensive income (loss), pretax | (1) | 129 | 128 | ||||||||||||||
Tax | (10) | — | (10) | ||||||||||||||
Other comprehensive income (loss), net of taxes | (11) | 129 | 118 | ||||||||||||||
Net transfer of benefit plans to (from) Merck affiliates | 11 | — | 11 | ||||||||||||||
Balance at September 30, 2021, net of taxes
|
$ | (32) | $ | (461) | $ | (493) |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
($ in millions) | U.S. | Int’l | Total | U.S. | Int’l | Total | U.S. | Int’l | Total | U.S. | Int’l | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Women’s Health | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nexplanon/Implanon NXT | $ | 120 | $ | 55 | $ | 175 | $ | 137 | $ | 52 | $ | 189 | $ | 389 | $ | 154 | $ | 543 | $ | 374 | $ | 142 | $ | 515 | |||||||||||||||||||||||||||||||||||||||||||||||
Follistim AQ | 29 | 32 | 61 | 20 | 31 | 50 | 81 | 97 | 178 | 60 | 75 | 135 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NuvaRing
|
21 | 28 | 49 | 25 | 33 | 58 | 68 | 79 | 147 | 86 | 98 | 184 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ganirelix Acetate Injection
|
5 | 20 | 25 | 4 | 21 | 25 | 19 | 66 | 85 | 7 | 48 | 55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cerazette
|
— | 18 | 18 | — | 18 | 18 | — | 53 | 53 | — | 51 | 51 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Women's Health (1)
|
18 | 35 | 53 | 45 | 39 | 84 | 80 | 111 | 191 | 121 | 103 | 224 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biosimilars | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Renflexis | 48 | 6 | 54 | 34 | 4 | 38 | 119 | 17 | 136 | 88 | 8 | 96 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ontruzant | 9 | 47 | 56 | — | 37 | 37 | 20 | 81 | 101 | 1 | 77 | 78 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brenzys | — | 14 | 14 | — | 23 | 23 | — | 35 | 35 | — | 52 | 52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Biosimilars (1)
|
— | 16 | 16 | — | 1 | 1 | — | 34 | 34 | — | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Established Brands | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardiovascular | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zetia | 1 | 90 | 91 | (1) | 103 | 103 | 6 | 276 | 282 | (4) | 389 | 384 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vytorin | 3 | 38 | 41 | 3 | 44 | 47 | 8 | 119 | 127 | 9 | 130 | 139 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atozet | — | 114 | 114 | — | 111 | 111 | — | 347 | 347 | — | 348 | 348 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rosuzet | — | 15 | 15 | — | 32 | 32 | — | 48 | 48 | — | 94 | 94 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cozaar/Hyzaar | 3 | 84 | 87 | 5 | 86 | 91 | 9 | 256 | 265 | 17 | 274 | 291 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zocor | 1 | 17 | 18 | 1 | 17 | 18 | 3 | 46 | 49 | 1 | 56 | 57 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Cardiovascular (1)
|
— | 31 | 31 | — | 37 | 37 | — | 99 | 99 | — | 124 | 124 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Respiratory | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Singulair | 2 | 98 | 100 | 4 | 78 | 82 | 10 | 289 | 300 | 14 | 324 | 338 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nasonex | — | 49 | 48 | — | 41 | 41 | 3 | 141 | 144 | 9 | 151 | 160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dulera | 48 | 8 | 56 | 51 | 8 | 59 | 121 | 25 | 146 | 155 | 26 | 181 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clarinex | 2 | 27 | 28 | 2 | 23 | 25 | 5 | 78 | 83 | 5 | 104 | 109 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asmanex | 14 | 2 | 15 | 20 | 1 | 21 | 43 | 5 | 48 | 58 | 5 | 64 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Respiratory (1)
|
— | 3 | 3 | — | 11 | 11 | — | 15 | 16 | 1 | 25 | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-Opioid Pain, Bone and Dermatology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arcoxia | — | 65 | 65 | — | 68 | 68 | — | 184 | 184 | — | 204 | 204 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fosamax | 1 | 45 | 46 | 1 | 45 | 46 | 3 | 130 | 132 | 3 | 137 | 140 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diprospan | — | 34 | 34 | — | 33 | 33 | — | 92 | 92 | — | 87 | 87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diprosone | — | 22 | 22 | — | 22 | 22 | 1 | 64 | 65 | 1 | 58 | 59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Non-Opioid Pain, Bone and Dermatology (1)
|
9 | 47 | 57 | 3 | 49 | 52 | 11 | 137 | 148 | 5 | 140 | 144 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proscar | — | 27 | 27 | — | 59 | 60 | 1 | 91 | 92 | 1 | 152 | 154 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Propecia | 1 | 33 | 34 | 2 | 30 | 32 | 5 | 96 | 101 | 7 | 83 | 91 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sinemet | — | 17 | 17 | — | 18 | 18 | — | 54 | 54 | (1) | 58 | 58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Remeron | 1 | 17 | 19 | 1 | 16 | 16 | 3 | 48 | 51 | 2 | 46 | 47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (1)
|
9 | 49 | 59 | 15 | 48 | 63 | 29 | 128 | 157 | 44 | 135 | 179 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (2)
|
1 | 51 | 52 | (1) | 3 | 2 | (2) | 171 | 168 | 4 | 46 | 50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total sales | $ | 346 | $ | 1,254 | $ | 1,600 | $ | 371 | $ | 1,242 | $ | 1,613 | $ | 1,035 | $ | 3,666 | $ | 4,701 | $ | 1,068 | $ | 3,851 | $ | 4,919 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Europe and Canada | $ | 410 | $ | 426 | $ | 1,314 | $ | 1,286 | |||||||||||||||
United States | 346 | 371 | 1,035 | 1,068 | |||||||||||||||||||
Asia Pacific and Japan | 287 | 354 | 874 | 1,190 | |||||||||||||||||||
China | 252 | 225 | 693 | 655 | |||||||||||||||||||
Latin America, Middle East, Russia and Africa | 238 | 228 | 595 | 649 | |||||||||||||||||||
Other(1)
|
67 | 9 | 190 | 71 | |||||||||||||||||||
$ | 1,600 | $ | 1,613 | $ | 4,701 | $ | 4,919 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Cost of sales | $ | — | $ | 122 | $ | 69 | $ | 375 | |||||||||||||||
Selling, general and administrative | — | 155 | 134 | 483 | |||||||||||||||||||
Research and development | — | 41 | 35 | 119 | |||||||||||||||||||
$ | — | $ | 318 | $ | 238 | $ | 977 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Included in continuing operations | |||||||||||||||||||||||
Supply sales to Merck affiliates | $ | — | $ | — | $ | 143 | $ | — | |||||||||||||||
Purchases from Merck affiliates | — | — | 65 | — | |||||||||||||||||||
Cost reimbursements and fees from Merck affiliates | — | — | 1 | — | |||||||||||||||||||
Included in discontinued operations | |||||||||||||||||||||||
Supply sales to Merck affiliates | $ | — | $ | 169 | $ | 12 | $ | 467 | |||||||||||||||
Purchases from Merck affiliates | 236 | 53 | 866 |
($ in millions) | December 31, 2020 | ||||
Included in continuing operations | |||||
Short term borrowings, net | $ | 1,512 | |||
Short term loans and notes payable, net | — | ||||
Trade payables (receivables), net | (173) | ||||
Due to related party | $ | 1,339 | |||
Included in discontinued operations | |||||
Short term loans receivables, net | $ | 247 | |||
Short term notes payable, net | (25) | ||||
Trade payables, net | (33) | ||||
Due from related party | $ | 189 |
Nine Months Ended September 30, | |||||||||||
($ in millions) |
2021(1)
|
2020 | |||||||||
Cash pooling and general financing activities | $ | 168 | $ | 3,099 | |||||||
Cost allocations, excluding non-cash stock-based compensation | (209) | (945) | |||||||||
Taxes deemed settled with Merck | (259) | (400) | |||||||||
Allocated derivative and hedging (losses) gains | (88) | (85) | |||||||||
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations(2)
|
$ | (388) | $ | 1,669 | |||||||
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations | 597 | (202) | |||||||||
Total net transfers to Merck as included in the Condensed Consolidated Statement of Cash Flows | $ | 209 | $ | 1,467 | |||||||
Stock-based compensation expense (includes $3 and $7 of discontinued operations for the nine months ended September 30, 2021 and 2020, respectively)
|
(32) | (43) | |||||||||
Net assets contributed by Merck affiliates | (778) | (10) | |||||||||
Recognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates
|
13 | — | |||||||||
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Equity
|
$ | (588) | $ | 1,414 |
Three Months Ended September 30, | |||||||||||
($ in millions) | 2021 | 2020 | |||||||||
Cash pooling and general financing activities | $ | — | $ | 971 | |||||||
Net assets distributed to (contributed by) Merck Affiliates | — | — | |||||||||
Cost allocations | (322) | ||||||||||
Income taxes deemed settled with Parent | — | (300) | |||||||||
Allocated derivative and hedging gains (losses) | — | (88) | |||||||||
Net transfers to Parent as reflected in the Condensed Consolidated Statement of Equity | $ | — | $ | 261 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||
Sales | $ | — | $ | 433 | $ | 93 | $ | 1,316 | |||||||||||||||||||||||||||
Costs, Expenses and Other | |||||||||||||||||||||||||||||||||||
Cost of Sales | — | 353 | 65 | 1,065 | |||||||||||||||||||||||||||||||
Selling, general and administrative | — | 80 | 15 | 248 | |||||||||||||||||||||||||||||||
Research and development | — | 29 | 4 | 78 | |||||||||||||||||||||||||||||||
Restructuring costs | — | 3 | — | 8 | |||||||||||||||||||||||||||||||
Other (income) expense, net | — | (24) | 4 | (12) | |||||||||||||||||||||||||||||||
Income (loss) from discontinued operations before taxes | $ | — | $ | (8) | $ | 5 | $ | (71) | |||||||||||||||||||||||||||
Taxes on income | — | 5 | 5 | 17 | |||||||||||||||||||||||||||||||
Loss from discontinued operations, net of taxes | $ | — | $ | (13) | $ | — | $ | (88) |
($ in millions) | December 31, 2020 | ||||
Assets | |||||
Cash and cash equivalents | $ | 58 | |||
Accounts receivable | 322 | ||||
Inventories | 58 | ||||
Due from related party | 189 | ||||
Other current assets | 47 | ||||
Total current assets of discontinued operations | 674 | ||||
Property, Plant and Equipment, net | 14 | ||||
Other Noncurrent Assets | 77 | ||||
Total Noncurrent Assets of Discontinued Operations | 91 | ||||
Total Assets of Discontinued Operations | $ | 765 | |||
Liabilities | |||||
Trade accounts payable | $ | 35 | |||
Accrued and other current liabilities | 93 | ||||
Total current liabilities of discontinued operations | 128 | ||||
Deferred Income Taxes | — | ||||
Other Noncurrent Liabilities | 83 | ||||
Total Noncurrent Liabilities of Discontinued Operations | 83 | ||||
Total Liabilities of Discontinued Operations | $ | 211 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
($ in millions and shares in thousands, except per share amounts) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
Net income attributable to Organon: | |||||||||||||||||||||||
Income from continuing operations | $ | 323 | $ | 560 | $ | 1,149 | $ | 1,880 | |||||||||||||||
Income from discontinued operations | — | (13) | — | (88) | |||||||||||||||||||
Net income attributable to Organon | $ | 323 | $ | 547 | $ | 1,149 | $ | 1,792 | |||||||||||||||
Basic weighted average number of shares outstanding | 253,534 | 253,516 | 253,530 | 253,516 | |||||||||||||||||||
Stock awards and equity units (share equivalent) | 638 | — | 481 | — | |||||||||||||||||||
Diluted weighted average common shares outstanding | 254,172 | 253,516 | 254,011 | 253,516 | |||||||||||||||||||
Earnings (Loss) Per Share Attributable to Organon common stockholders - Basic | |||||||||||||||||||||||
Income from continuing operations | $ | 1.27 | $ | 2.21 | $ | 4.53 | $ | 7.42 | |||||||||||||||
Loss from discontinued operations | — | (0.05) | — | (0.35) | |||||||||||||||||||
Basic earnings per common share attributable to Organon common stockholders | $ | 1.27 | $ | 2.16 | $ | 4.53 | $ | 7.07 | |||||||||||||||
Earnings (Loss) Per Share Attributable to Organon common stockholders - Diluted | |||||||||||||||||||||||
Income from continuing operations | 1.27 | 2.21 | 4.52 | 7.42 | |||||||||||||||||||
Loss from discontinued operations | — | (0.05) | — | (0.35) | |||||||||||||||||||
Diluted earnings per common share attributable to Organon common stockholders | $ | 1.27 | $ | 2.16 | $ | 4.52 | $ | 7.07 |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
United States | $ | 346 | $ | 371 | (7) | % | (7) | % | $ | 1,035 | $ | 1,068 | (3) | % | (3) | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
International | 1,254 | 1,242 | 1 | % | (2) | % | 3,666 | 3,851 | (5) | % | (9) | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 1,600 | $ | 1,613 | (1) | % | (3) | % | $ | 4,701 | $ | 4,919 | (4) | % | (8) | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Nexplanon/Implanon NXT | $ | 175 | $ | 189 | (7) | % | (8) | % | $ | 543 | $ | 515 | 5 | % | 4 | % | |||||||||||||||||||||||||||||||
NuvaRing | 49 | 58 | (16) | % | (17) | % | 147 | 184 | (20) | % | (22) | % | |||||||||||||||||||||||||||||||||||
Follistim AQ | 61 | 50 | 21 | % | 18 | % | 178 | 135 | 31 | % | 26 | % | |||||||||||||||||||||||||||||||||||
Ganirelix Acetate Injection | 25 | 25 | (2) | % | (5) | % | 85 | 55 | 53 | % | 46 | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Renflexis | $ | 54 | $ | 38 | 44 | % | 43 | % | $ | 136 | $ | 96 | 41 | % | 39 | % | |||||||||||||||||||||||||||||||
Ontruzant | 56 | 37 | 48 | % | 47 | % | 101 | 78 | 29 | % | 24 | % | |||||||||||||||||||||||||||||||||||
Brenzys | 14 | 23 | (40) | % | (42) | % | 35 | 52 | (33) | % | (38) | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Zetia/Vytorin | $ | 132 | $ | 150 | (11) | % | (15) | % | $ | 409 | $ | 523 | (22) | % | (26) | % | |||||||||||||||||||||||||||||||
Atozet | 114 | 111 | 3 | % | 1 | % | 347 | 348 | — | % | (6) | % | |||||||||||||||||||||||||||||||||||
Rosuzet | 15 | 32 | (52) | % | (51) | % | 48 | 94 | (49) | % | (49) | % | |||||||||||||||||||||||||||||||||||
Cozaar/Hyzaar | 87 | 91 | (4) | % | (7) | % | 265 | 291 | (9) | % | (14) | % | |||||||||||||||||||||||||||||||||||
Zocor | 18 | 18 | (1) | % | (3) | % | 49 | 57 | (15) | % | (19) | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Singulair | $ | 100 | $ | 82 | 22 | % | 20 | % | $ | 300 | $ | 338 | (11) | % | (15) | % | |||||||||||||||||||||||||||||||
Nasonex | 48 | 41 | 18 | % | 13 | % | 144 | 160 | (11) | % | (15) | % | |||||||||||||||||||||||||||||||||||
Dulera | 56 | 59 | (5) | % | (6) | % | 146 | 181 | (19) | % | (20) | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Arcoxia | $ | 65 | $ | 68 | (5) | % | (7) | % | $ | 184 | $ | 204 | (10) | % | (13) | % |
Three Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||||||||||||||
Proscar | $ | 27 | $ | 60 | (53) | % | (56) | % | $ | 92 | $ | 154 | (40) | % | (44) | % |
Three Months Ended September 30, | % Change | Nine Months Ended September 30, | % Change | ||||||||||||||||||||||||||||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||||
Cost of sales | $ | 609 | $ | 535 | 14 | % | $ | 1,783 | $ | 1,533 | 16 | % | |||||||||||||||||||||||
Selling, general and administrative | 388 | 321 | 21 | % | 1,186 | 922 | 29 | % | |||||||||||||||||||||||||||
Research and development | 111 | 54 | 106 | % | 254 | 150 | 69 | % | |||||||||||||||||||||||||||
Restructuring costs | 1 | 12 | * | 3 | 43 | * | |||||||||||||||||||||||||||||
Other (income) expense, net | 102 | 10 | * | 182 | 44 | * | |||||||||||||||||||||||||||||
$ | 1,211 | $ | 932 | 30 | % | $ | 3,408 | $ | 2,692 | 27 | % |
Number
|
Description
|
||||||||||
2.1 |
—
|
||||||||||
3.1 |
—
|
||||||||||
3.2 |
—
|
||||||||||
†10.1 |
—
|
||||||||||
10.2 |
—
|
||||||||||
†10.3 |
—
|
||||||||||
†10.4 |
—
|
||||||||||
10.5 |
—
|
||||||||||
10.6 |
—
|
||||||||||
10.7 |
—
|
||||||||||
10.8 |
—
|
||||||||||
10.9 |
—
|
||||||||||
10.10 |
—
|
||||||||||
10.11 |
—
|
** | Furnished herewith | ||||||||||
† | Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished. |
ORGANON & CO.
|
||||||||
Date: November 12, 2021
|
/s/ Kathryn DiMarco | |||||||
Kathryn DiMarco | ||||||||
Senior Vice President Finance - Corporate Controller | ||||||||
Date: November 12, 2021
|
/s/ Matthew Walsh | |||||||
Matthew Walsh | ||||||||
Chief Financial Officer
|
ORGANON
|
||
NON-EMPLOYEE DIRECTOR SAVINGS | ||
PLAN | ||
2
|
3
|
4
|
5
|
If primary reason your employment ends is due to:
|
Here’s what happens to your unvested Restricted Stock Units (RSUs):
|
||||
Voluntary Termination
Misconduct
Termination for poor performance or for Cause
|
An unvested portion of the RSU Award and accrued dividend equivalents will be forfeited on the date your employment ends.
|
||||
Involuntary Termination not for poor performance, or without Cause
Retirement Death Disability
|
A pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by the total number of months during the Restricted Period of the grant1, reduced by the number of RSUs that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.
|
||||
Sale (for example, sale of your subsidiary, division or JV)
|
The following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued:
•one-third if employment terminates on or after the Grant Date but before the first anniversary thereof (the remainder will be forfeited on the date your employment ends); and
•all if employment terminates on or after the first anniversary of the Grant Date.
|
||||
Change in Control of the Company
|
If this RSU Award remains outstanding following a Change in Control and is converted into a successor RSU Award, any unvested portion becomes payable on the scheduled Vesting Date(s) subject to your continuous employment.
If the Employer or the Company or a parent, subsidiary, affiliate, or JV of the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary of the closing of any Change in Control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this RSU Award.
If this RSU does not remain outstanding following the Change in Control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Organon stockholders for a share of Organon common stock in the Change in Control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire.
|
Country |
Additional Terms and Conditions, and notifications
|
||||
Australia
|
Notifications
Australia Offer Document
The Company is pleased to provide you with this offer to participate in the Plan. This offer document sets out information regarding the offer to participate in the Plan for Australian resident grantees of the Company and its subsidiaries, affiliates and joint ventures. This information is provided by the Company to ensure compliance of the offer with Australian Securities and Investments Commission (“ASIC”) Class Order 14/1000, ASIC Regulatory Guide 49 and relevant provisions of the Corporations Act 2001.
Additional Documents. In addition to the information set out in this supplement, you are also being provided with copies of the following documents:
(a)the Plan;
(b)the Plan Prospectus (which contains a summary of the Plan);
(c)the Terms;
(d)LTI Program Overview (available in the Company’s intranet site, Hera, under LTI page); and
(e)the summary of tax consequences of participation in the Plan for Australia, which is accessible by logging into your account at Morgan Stanley
(collectively, the “Additional Documents”).
The Additional Documents provide further information to help you make an informed investment decision about participating in the Plan. Neither the Plan nor the Plan Prospectus is a prospectus for the purposes of the Corporations Act 2001.
You should not rely upon any oral statements made in relation to this offer. You should rely only upon the statements contained in this supplement and the Additional Documents when considering participation in the Plan.
General Information Only. The information herein is general information only. It is not advice or information that takes into account your objectives, financial situation and needs.
You should consider obtaining your own financial product advice from a person who is licensed by ASIC to give such advice.
Risk Factors. Investment in shares of common stock involves a degree of risk. If you elect to participate in the Plan, you should monitor your participation and consider all risk factors relevant to the vesting or issuance of shares of common stock under the Plan as set forth below and in the Additional Documents.
You should have regard to risk factors relevant to investment in securities generally and, in particular, to holding shares of common stock of the Company. For example, the value at which an individual share of common stock is quoted on the New York Stock Exchange (“NYSE”) may increase or decrease due to a number of factors. There is no guarantee that the value of a share of common stock will increase. Factors that may affect the value of an individual share of common stock include fluctuations in the domestic and international market for listed stocks, general economic conditions, including interest rates, inflation rates, commodity and oil prices, changes to government fiscal, monetary or regulatory policies, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.
More information about potential factors that could affect the Company’s business and financial results will be included in the Company’s most recent Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q. Copies of these reports are available at http://www.sec.gov/, on the Company’s “Investor Relations” page at https://www.organon.com/investor-relations/ and upon request to the Company.
In addition, you should be aware that the Australian dollar (“AUD”) value of any shares of common stock acquired under the Plan will be affected by the USD/AUD exchange rate. Participation in the Plan involves certain risks related to fluctuations in this rate of exchange.
Common Stock in a U.S. Corporation. Common stock of a U.S. corporation is analogous to ordinary shares of an Australian corporation. Each holder of a share of common stock is entitled to one vote. Further, shares of common stock are not liable to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.
Ascertaining the Market Value of Shares of Common Stock. You may ascertain the current market value of an individual share of common stock as traded on the NYSE under the symbol “OGN” at:
|
https://www.nyse.com/quote/XNYS:OGN. The AUD equivalent of that value can be obtained at: https://www.rba.gov.au/statistics/frequency/exchange-rates.html.
This will not be a prediction of the market value of an individual share of common stock when the RSU Award vests or shares of common stock are issued under the Plan or of the applicable exchange rate on the Vesting Date or the date the shares of common stock are issued.
Exchange Control Notification
Exchange control reporting is required for cash transactions exceeding A$10,000 and international fund transfers of any amount. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report yourself.
Tax Information
The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Tax Assessment Act”) applies (subject to the conditions in the Tax Assessment Act).
|
|||||
Austria
|
Notifications
Exchange Control Notification
If you hold shares of common stock acquired under the Plan outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares of common stock as of any given quarter does not meet or exceed €30,000,000 or as of December 31 does not meet or exceed €5,000,000. If the former threshold is met or exceeded, quarterly obligations are imposed, whereas if the latter threshold is met or exceeded, annual reports must be filed with the Austrian National Bank. The deadline for filing the quarterly report is the 15th day of the month following the end of the relevant quarter. The deadline for filing the annual report is January 31st of the following year.
When you sell shares of common stock issued upon expiration of the Restricted Period under the Plan, there may be exchange control obligations if the cash received is held outside Austria. If the transaction volume of all your accounts abroad meets or exceeds €10,000,000, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month.
|
Belgium
|
Notifications
Foreign Asset/Account Reporting Notification
You are required to report any securities held (including shares of common stock) and brokerage or bank accounts (including any brokerage account held by you at Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future) opened and maintained outside Belgium on your annual tax return. The first time you report the account(s) on your annual income tax return, you will have to provide the National Bank of Belgium Central Contact Point with certain details regarding such foreign accounts (including the account number, broker or bank name and country in which any such account was opened) in a separate form. This form, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be under the Kredietcentrales / Centrales des credits caption. You should consult with your personal tax advisor to determine your personal reporting obligations.
Annual Securities Accounts Tax Information
A new “annual securities accounts tax” has been implemented, which imposes a 0.15% annual tax on the value of the qualifying securities held in a Belgian or foreign securities account. The tax will not apply unless the total value of securities held in such account exceeds EUR 1 million on average on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30). The tax will first be due for the period starting on the day of entry into force of the implementing law (i.e., February 26, 2021) and ending on September 30, 2021. For future, the tax will be due for periods starting October 1 and ending September 30. Different payment obligations apply depending on whether the securities account is held with a Belgian or foreign financial institution. You should consult your personal tax advisor for more information regarding your annual securities accounts tax payment obligations.
For avoidance of doubt, the stock exchange tax that had applied to transactions executed by a Belgian resident through a non-Belgian financial intermediary was eliminated as the result of a ruling by the Belgian Constitutional Court on October 17, 2019.
|
||||
Bosnia |
There are no country-specific provisions.
|
||||
Brazil |
Terms and Conditions
|
Compliance with Law
By accepting the RSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the expiration of the Restricted Period, the sale of shares obtained pursuant to the expiration of the Restricted Period, and the receipt of any dividends or dividend equivalents.
Labor Law Acknowledgment
By accepting the RSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of common stock is not fixed and may increase or decrease in value over the Restricted Period without compensation to you.
Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service; (ii) the Plan is not a part of the terms and conditions of your employment or service; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.
Notifications
Foreign Asset/Account Reporting Notification
If you hold assets and rights outside Brazil with an aggregate value exceeding US$1,000,000, and you are a resident or domiciled in Brazil, you will be required to prepare and submit to the Central Bank of Brazil an annual declaration of such assets and rights. Assets and rights that must be reported include shares of the Company’s common stock acquired or the receipt of any dividends or dividend equivalents paid under the Plan. Please note that the US$1,000,000 threshold may be changed annually and that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement.
If the value of the shares of common stock you receive under the Plan exceeds BRL 5,000, you must report the shares acquired in the assets and rights section of the annual Natural Person Income Tax Return typically due by the last business day of April.
Tax Notification
Payments to foreign countries and repatriation of funds into Brazil (including proceeds from the sale of shares of common stock) and the conversion of USD into BRL associated with such fund transfers may be subject to the Tax on Financial Transactions. It is your responsibility to comply with any applicable Tax on Financial Transactions arising from your participation in the Plan. You should consult with your personal tax advisor for additional details.
|
|||||
Bulgaria
|
Notifications
Foreign Asset/Account Reporting Notification
If the total value of cash or securities (including shares obtained pursuant to the expiration of the Restricted Period) held by you, in a foreign bank or brokerage account, equals or exceeds BGN 50,000 as of December 31st, you may be required to file statistical forms with the Bulgarian National Bank. If required, the forms must be filed by March 31st of the following year. You must also report the acquisition of shares of common stock under the Plan on your annual tax return in the year of acquisition and in each subsequent annual tax return for as long as you hold the shares. If you have any questions regarding these obligations, you should contact your local bank in Bulgaria.
|
||||
Canada
|
Terms and Conditions Termination of Employment
This provision replaces paragraph (9) of the “Nature of Grant” section in Part A of this Appendix:
Except to the extent explicitly required under local employment standards legislation, the RSU Award and any shares of common stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company;
This provision replaces paragraph (11) of the “Nature of Grant” section in Part A of this Appendix:
Except to the extent explicitly required under local employment standards legislation, no claim or entitlement to compensation or damages shall arise from termination of the RSU Award resulting from termination of your
|
employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);
This provision replaces paragraph (12) of the “Nature of Grant” section in Part A of this Appendix:
For purposes of the RSU Award, except to the extent expressly provided in your Terms or expressly required by applicable legislation, your employment relationship will be considered terminated (regardless of the reason for such termination) and your right to vest in the RSU Award under the Plan, if any, will terminate as of the date that is the earliest of (a) the date you are no longer employed or providing services to the Company or any parent, subsidiary, affiliate or joint venture, (b) the date you receive written notice of termination of employment, or (c) the date written notice of termination is delivered to your last known address (together, the “Termination Date”). Except to the extent explicitly required by applicable legislation, the Termination Date will exclude any notice period or period of pay in lieu of such notice required under statute, contract, common/civil law or otherwise. You will not earn, or be entitled to earn, any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. In case of any dispute as to whether termination of employment has occurred that cannot be reasonably determined under your Terms and the Plan, the Committee shall have the sole discretion, subject to applicable legislation, to determine whether such termination of employment has occurred and the effective date of such termination.
Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the RSU Award under the Plan, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the Vesting Date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.
Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of common stock only.
The following provisions will apply to you if you are a resident of Quebec:
Language Consent
The parties acknowledge that it is their express wish that the Terms, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.
Les parties reconnaissent avoir exigé la rédaction en anglais de la convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaries intentées, directement ou indirectement, relativement à ou suite à la présente convention.
Data Privacy
This provision supplements the “Data Privacy” section in the Terms:
You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, and its subsidiaries, affiliates or joint ventures and Morgan Stanley Smith Barney and any other stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors. You further authorize the Company and its subsidiaries, affiliates and joint ventures to record such information and to keep such information in your employee file.
Notifications
Securities Law Information
You are permitted to sell shares of common stock acquired through the Plan through the broker designated by the Company under the Plan, if any, provided the resale of shares of common stock acquired under the Plan takes place outside of Canada through the facilities of a stock exchange on which the shares of common stock are listed. The shares are currently listed on the New York Stock Exchange.
Foreign Asset/Account Reporting Notification
Specified foreign property, including shares of common stock, Incentives and other rights to receive shares of a non-Canadian company held by a Canadian resident employee must generally be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee’s foreign specified property exceeds
C$100,000 at any time during the year. The Form T1135 must be filed by April of the following year. Thus, such Incentives must be reported - generally at a nil cost - if the C$100,000 cost threshold is exceeded because other
|
foreign property is held by the employee. When shares of common stock are acquired, their cost generally is the adjusted cost base (“ACB”) of the shares of common stock. The ACB would ordinarily equal the fair market value of the shares of common stock at the time of acquisition, but if the employee owns other shares of common stock of the same company, this ACB may have to be averaged with the ACB of the other shares of common stock. Canadian residents should consult with their personal tax advisors to ensure compliance with their reporting requirements.
|
|||||
Chile
|
Notifications
Securities Law Information
THE OFFER OF THE AWARD CONSTITUTES A PRIVATE OFFERING OF SECURITIES IN CHILE EFFECTIVE AS OF THE GRANT DATE. THE OFFER OF AWARD IS MADE SUBJECT TO GENERAL RULING N° 336 OF THE CHILEAN COMMISSION OF THE FINANCIAL MARKET (“CMF”). THE OFFER REFERS TO SECURITIES NOT REGISTERED AT THE SECURITIES REGISTRY OR AT THE FOREIGN SECURITIES REGISTRY OF THE CMF, AND, THEREFORE, SUCH SECURITIES ARE NOT SUBJECT TO OVERSIGHT OF THE CMF. GIVEN THAT THE AWARD IS NOT REGISTERED IN CHILE, THE COMPANY IS NOT REQUIRED TO PROVIDE PUBLIC INFORMATION ABOUT THE AWARD OR SHARES OF COMMON STOCK IN CHILE. UNLESS THE AWARD AND/OR THE SHARES OF COMMON STOCK ARE REGISTERED WITH THE CMF, A PUBLIC OFFERING OF SUCH SECURITIES CANNOT BE MADE IN CHILE.
Exchange Control and Tax Information
You must comply with the exchange control and tax reporting requirements in Chile when sending funds into the country in connection with the sale of shares of common stock acquired under the Plan, and register any investments with the Chilean Internal Revenue Service (the “CIRS”). You should consult with your personal legal advisor regarding any applicable exchange control obligations prior to vesting in the RSU Award or receiving proceeds from the sale of shares acquired at vesting, dividends or dividend equivalents and how to register with the CIRS.
You are not required to repatriate funds obtained from the sale of shares of common stock or the receipt of any dividends or dividend equivalents. However, if you decide to repatriate such funds, you must do so through the Formal Exchange Market (i.e., a commercial bank or registered foreign exchange office) if the funds exceed US$10,000. In such case, you must report the payment to a commercial bank or registered foreign exchange office receiving the funds. The commercial bank or registered foreign exchange office will then submit an affidavit to the Central Bank within a day of receipt of the foreign currency.
If your aggregate investments held outside of Chile exceed US$5,000,000 or its equivalent in other foreign currencies (including the investments made under the Plan), you must inform the Central Bank of Chile with updated information accumulated for a three month period, within and no later than the first 45 calendar days following the closing of the months of March, June and September, and no later than 60 calendar days following the closing of the month of December, by means of providing the completed form of Annex 3.1 (and of Annex 3.2 at the closing of December if applicable) of Chapter XII of the Exchange Regulations Manual. Please note that exchange control regulations in Chile are subject to change.
Foreign Asset/Account Reporting Notification
The CIRS requires all taxpayers to provide information annually regarding (i) the results of investments held abroad and (ii) any taxes paid abroad which the taxpayers will use as credit against Chilean income tax. The sworn statements disclosing this information (or Formularios) must be reported on Form 1929 and submitted electronically through the CIRS website www.sii.cl before July 1 of each year, depending on the assets and/or taxes being reported. If you fail to meet the above requirements, you may be ineligible to receive certain foreign tax credits. Given these requirements are subject to change, you should consult with your personal legal advisor to ensure compliance with the applicable requirements.
|
||||
The People’s
Republic of China
|
Terms and Conditions Payment of Award
Any Award granted to you will be settled in cash only. This means that upon vesting of your Award, you will receive in cash the value of the underlying shares of common stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll.
|
Colombia
|
Terms and Conditions Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part A of this Appendix:
You acknowledge that pursuant to Article 128 of the Colombian Labor Code, the Plan, the RSU Award and any income realized under the Plan do not constitute a component of your “salary”. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.
Notifications
Foreign Asset/Account Reporting Notification
Colombian residents must file an annual information return with the Colombian Tax Office detailing any assets (such as shares of common stock acquired under the Plan) held abroad. If the individual value of any of these assets exceeds a certain threshold, you must describe each asset and indicate the jurisdiction in which it is located, its nature and its value.
Securities Law Information.
The shares of common stock are not and will not be registered with the Colombian registry of publicly traded securities (Registro Nacional de Valores y Emisores) and therefore the shares of common stock may not be offered to the public in Colombia. Nothing in this supplement should be construed as the making of a public offer of securities in Colombia.
Exchange Control Notification
You are responsible for complying with any and all Colombian foreign exchange restrictions, approvals and reporting requirements in connection with the RSU Award and any shares of common stock acquired or funds received under the Plan. This includes reporting obligations to the Central Bank (Banco de la Republica). You will also be required to register your investments with the Central Bank, regardless of the value of the investment by filing a Form No. 11 any time before disposing of shares of common stock. All payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (e.g. local banks), which includes the obligation of correctly completing and filing the appropriate foreign exchange form (declaración de cambio). You should consult with your personal legal advisor regarding any your exchange control obligations.
|
||||
Costa Rica
|
There are no country-specific provisions.
|
||||
Croatia
|
Notifications
Exchange Control Notification
Croatian residents may be required to report any acquisition of foreign securities (such as shares of the Company’s common stock) to the Croatian National Bank for statistical purposes. However, because exchange control regulations may change without notice, you should consult your personal legal advisor to ensure compliance with current regulations. It is your responsibility to comply with Croatian exchange control laws.
|
||||
Cyprus |
There are no country-specific provisions.
|
||||
Czech Republic
|
Notifications
Exchange Control Notification
You may be required to notify the Czech National Bank (“CNB”) that you acquired shares under the Plan and/or that you maintain a foreign account. Such notification will be required if the aggregate value of your foreign direct investments is CZK 2,500,000 or more, you have a certain threshold of foreign financial assets, or you are specifically requested to do so by the Czech National Bank. Exchange control regulations change frequently and without notice; therefore, you should consult with your legal advisor prior to the sale of shares of common stock to ensure compliance with current regulations. It is your responsibility to comply with Czech exchange control laws, and neither the Company nor your Employer will be liable for any resulting fines or penalties.
|
||||
Denmark |
Terms and Conditions
|
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part A of this Appendix:
By accepting the RSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.
Stock Option Act
You acknowledge that you received the Employer Statement (attached immediately below) which summarizes select terms of your RSU Award.
As set forth in Section 1 of the Stock Option Act, the Stock Option Act only applies to “employees” as that term is defined in Section 2 of the Stock Option Act and to the extent you are subject to Danish law. If you are a member of the registered management of the Company's subsidiary, affiliate or joint venture in Denmark or otherwise do not satisfy the definition of employee or are not subject to Danish law, you will not be subject to the Stock Option Act and the Employer Statement will not apply to you.
Notifications
Exchange Control and Tax Information
The Danish Tax Reporting Act that entered into force on January 1, 2019 removed the rules that previously obligated you to inform the Danish Tax Administration about shares of common stock held in foreign bank or brokerage accounts and deposit accounts with a foreign bank or broker. The use of the Forms V and K are discontinued as of January 1, 2019 and replaced by automatic exchange of information regarding bank and brokerage accounts. However, you must still report shares of common stock held in a foreign bank or brokerage account in your tax return under the section of foreign affairs and income.
Denmark Employer Statement
You acknowledge receipt of the Employer Statement attached as Appendix B to the Terms.
|
|||||
Ecuador
|
Notifications
Foreign Asset/Account Reporting Notification
You will be responsible for including any RSU Award that vested during the previous fiscal year in your annual Net Worth Declaration if your net worth exceeds the thresholds set forth in the law.
|
||||
Egypt
|
Notifications
Exchange Control Notification
If you transfer funds into Egypt in connection with the sale of shares of common stock or the receipt of any dividends or dividend equivalents, you are required to transfer the funds through a registered bank in Egypt.
|
||||
Estonia
|
Terms and Conditions Language Consent
By accepting the grant of the RSU Award, you confirm having read and understood the documents related to the grant (the Terms and the Plan), which were provided in the English language, and that you do not need the translation thereof into the Estonian language. You accept the terms of those documents accordingly.
Võttes vastu Award-de pakkumise kinnitad, et oled ingliskeelsena esitatud pakkumisega seotud dokumendid (Tingimused ja Plaan) läbi lugenud ja nendest aru saanud ning et ei vaja nende tõlkimist eesti keelde. Sellest tulenevalt nõustud viidatud dokumentide tingimustega.
|
||||
Finland
|
Notifications
Foreign Asset / Account Reporting Information.
There are no specific reporting requirements with respect to foreign assets/accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.
|
France
|
Terms and Conditions Language Consent
By accepting the RSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant l’attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions générales et dispositions, qui ont été transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.
Notifications Tax Notification
Your RSU Award is not intended to qualify for specific tax or social security treatment in France.
Foreign Asset/Account Reporting Notification
If you hold shares of common stock outside of France or maintain a foreign bank account, you are required to report same (including any accounts that were closed during the tax year) to the French tax authorities on Form No. 3916 which must be filed together with your annual tax return. Failure to comply could trigger significant penalties. You should consult with your personal tax advisor to ensure compliance with your reporting requirements.
|
||||
Germany
|
Notifications
Exchange Control Notification
Cross-border payments in excess of €12,500 in connection with the sale of securities must be reported on a monthly basis. If you make or receive a payment in excess of this amount, you must report the payment to Bundesbank electronically using the “General Statistics Reporting Portal” (“Allgemeines Meldeportal Statistik”) available via Bundesbank’s website (www.bundesbank.de).
Foreign Asset/Account Reporting Notification
If your acquisition of shares of common stock under the Plan leads to a so-called “qualified participation” at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year. A “qualified participation” is attained if (i) the value of the shares acquired exceeds EUR 150,000 (if you own 1% or more of the Company’s common stock) or (ii) in the unlikely event you hold shares of common stock exceeding 10% of the Company's total common stock.
|
||||
Greece
|
Notifications
Foreign Asset / Account Reporting Information.
The reporting of foreign assets (including shares and other investments) is your own obligation and should be done through your annual tax return.
|
Hong Kong
|
Terms and Conditions Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of common stock only.
Notifications
Securities Law Information
Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You should exercise caution in relation to the offer. If you are in any doubt about any of the contents of the Plan and the Terms, including this supplement, you should obtain independent professional advice. The RSU Award and any shares of common stock issued pursuant to the RSU Award do not constitute a public offering of securities under Hong Kong law and are available only to Eligible Employees of the Company or its subsidiaries, affiliates and joint ventures. The Terms, including this supplement, the Plan and other incidental communication materials distributed in connection with the RSU Award (i)have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each Eligible Employee of the Employer, the Company or its subsidiaries, affiliates and joint ventures and may not be distributed to any other person.
|
Sale of Shares
Shares of common stock received at vesting are accepted as a personal investment. In the event the Restricted Period on your RSU Award expires within six months of the Grant Date and shares of common stock are issued to you, you agree that you will not offer to the public or otherwise dispose of the shares of common stock prior to the six-month anniversary of the Grant Date.
|
|||||
Hungary
|
Terms and Conditions Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of common stock at vesting, less any Tax-Related
Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of common stock and to force the immediate sale of such shares of common stock depending on the development of applicable exchange control laws and regulations.
|
India
|
Notifications
Exchange Control Notification
You understand that you must repatriate any proceeds from the sale of shares of common stock under the Plan and any dividends or any dividend equivalents received in relation to the shares of common stock to India and convert the proceeds into local currency within such time as prescribed under applicable Indian exchange control laws as may be amended from time to time. You must obtain a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency and maintain the FIRC as evidence of the repatriation of funds in the event the Reserve Bank of India or the Employer requests proof of repatriation.
Foreign Asset/Account Reporting Notification
You are required to declare any foreign bank accounts and any foreign financial assets (including shares of common stock held outside of India) in your annual income tax return. It is your responsibility to comply with this reporting obligation and you should consult your personal legal advisor to determine whether the obligation applies to your personal situation.
|
||||
Indonesia
|
Notifications
Language Acknowledgment
A translation of the documents relating to this grant into Bahasa Indonesia can be provided to you upon request to widhi.lestari@organon.com. By accepting the RSU Award, you (i) confirm having read and understood the documents relating to this grant (i.e., your Terms, including this supplement, and the Plan) which were provided in the English language, (ii) accept the terms of these documents accordingly, and (iii) agree not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).
Persetujuan dan Pemberitahuan Bahasa
Terjemahan dari dokumen-dokumen terkait dengan pemberian inike Bahasa Indonesia dapat disediakan untuk anda berdasarkan permintaan kepada widhi.lestari@organon.com. Dengan menerima Penghargaan ini, anda (i) mengkonfirmasi bahwa telah membaca dan memahami dokumen-dokumen berkaitan dengan pemberian ini (yaitu, Syarat-syarat anda, termasuk suplemen ini dan Program) yang disediakan dalam Bahasa Inggris, (ii) menerima persyaratan di dalam dokumen-dokumen tersebut, dan (iii) setuju untuk tidak mengajukan keberatan atas keberlakuan dari dokumen ini berdasarkan Undang-Undang No. 24 Tahun 2009 tentang Bendera, Bahasa dan Lambang Negara serta Lagu Kebangsaan ataupun Peraturan Presiden sebagai pelaksanaannya (ketika diterbitkan).
Foreign Asset/Account Reporting Notification
You have the obligation to report your worldwide assets (including foreign accounts and shares of common stock acquired under the Plan) in your annual individual income tax return.
Exchange Control Notification
In general, no exchange control approvals are required in Indonesia. However, foreign exchange activity is subject to certain reporting requirements. For foreign currency transactions exceeding USD 25,000, the underlying
document of that transaction will have to be submitted to the relevant local bank. If there is a change of position of any the foreign assets you hold (including shares acquired under the Plan), you must report this change in position
|
(i.e., sale of shares) to the Bank of Indonesia no later than the 15th day of the month following the change in position.
For transactions of USD 10,000 or more (or its equivalent in other currency), a more detailed description of the transaction must be included in the report and you may be required to provide information about the transaction to the bank in order to complete the transaction.
|
|||||
Ireland |
There are no country-specific provisions.
|
||||
Israel
|
Notifications Tax Notification
Your RSU Award is not intended to be tax-qualified under Section 102 of the Income Tax Ordinance.
Securities Law Information
This offer of RSUs does not constitute a public offering under the Securities Law, 1968.
|
||||
Italy
|
Terms and Conditions
Plan Document Acknowledgment
By accepting the RSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms: (a) your RSU Award cannot be transferred other than by will or the laws of descent and distribution; (b) in the event of involuntary termination of your employment, your right to receive RSUs and to receive distributions from RSUs, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (d) you are responsible for all Tax-Related Items; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of common stock described in the Plan occurs, your RSU Award may be adjusted; (f) if a Change in Control, as described in the Plan, occurs, your RSU Award may immediately vest; (g) all decisions with respect to future grants will be at the sole discretion of the Company; and (h) the “Data Privacy” section of your Terms.
Notifications
Foreign Asset/Account Reporting Notification
If you are an Italian resident who, at any time during the fiscal year, holds foreign financial assets (including cash and shares of common stock acquired under the Plan) which may generate income taxable in Italy, you are required to report these assets on your annual tax return for the year during which the assets are held, or on a special form if no tax return is due. These reporting obligations also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.
Foreign Financial Asset Tax Information
Italian residents may be subject to tax on the value of financial assets (including cash and shares of common stock acquired under the Plan) held outside of Italy. The taxable amount will be the fair market value of the financial assets, assessed at the end of the calendar year. No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold. You should contact your personal tax advisor for additional information about the foreign financial assets tax.
|
||||
Japan
|
Notifications
Foreign Asset/Account Reporting Notification
You are required to report the details of any assets held outside of Japan as of December 31 (including shares of common stock acquired under the Plan) to the extent such assets have a total net fair market value in excess of
¥50,000,000. Such report will be due by March 15 of the following year. You should consult your personal legal and/or tax advisor to determine whether the reporting obligation applies to your personal situation and whether you will be required to report details of any outstanding RSUs or shares of common stock held by you in the report.
|
||||
Jordan |
There are no country-specific provisions.
|
||||
Korea | Notifications |
Foreign Asset/Account Reporting Notification
Korean residents must declare all foreign financial accounts (e.g., non-Korean bank accounts, brokerage accounts, etc.) they hold in any foreign country to the Korean tax authority and file a report with respect to such accounts if the monthly balance of such accounts exceeds KRW 500 million (or an equivalent amount in foreign currency) on any month-end date during a calendar year. The report is due in June of the following year. You should consult with your personal tax advisor to determine how to value your foreign accounts for purposes of this reporting requirement and whether you are required to file a report with respect to such accounts.
|
|||||
Kuwait
|
Notifications
Securities Law Information
The grant of RSUs and distribution of the Plan and the Terms, including this supplement, to Eligible Employees does not constitute the marketing or offering of securities in Kuwait pursuant to Law No. 7 of 2010 as amended (establishing the Capital Markets Authority) and its implementing regulations. Offers under the Plan are being made only to Eligible Employees of the Employer or the Company or any other subsidiary, affiliate or joint venture of the Company.
|
||||
Lebanon
|
Notifications
Securities Law Information
The grant of RSUs and distribution of the Plan and the Terms, including this supplement, to Eligible Employees does not constitute the marketing or offering of securities to the public in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offers under the Plan are being made only to Eligible Employees of the Employer or the Company or any other subsidiary, affiliate or joint venture of the Company.
|
||||
Malaysia
|
Notifications Director Notification
If you are a director of the Company’s Malaysian subsidiary, affiliate or joint venture, you are subject to certain notification requirements under the Malaysian Companies Act. Among these requirements is an obligation to notify the Malaysian subsidiary, affiliate or joint venture in writing when you receive or dispose of an interest (e.g., RSU Awards or shares of common stock) in the Company or any related company. Such notifications must be made within 14 days of receiving or disposing of any interest in the Company or any related company.
|
||||
Mexico
|
Terms and Conditions
Labor Law Acknowledgement
These provisions supplement the “Nature of Grant” section in Part A of this Appendix:
By accepting the RSU Award, you understand and agree that: (i) the RSU Award is not related to the salary and other contractual benefits granted to you by the Employer and (ii) any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Policy Statement
The invitation the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability to you.
The Company, with registered offices at 30 Hudson Street, Floor 33, Jersey City, NJ 07302 U.S.A., is solely responsible for the administration of the Plan and your participation in the Plan and the acquisition of shares of common stock does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis. Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participating in the Plan do not establish any rights between you and the Employer and do not form part of the employment conditions and/or benefits provided by the Employer, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, joint ventures, branches, representation offices, shareholders, officers, agents or legal representatives, with respect to any claim that may arise.
|
Plan Document Acknowledgment
By accepting the RSU Award, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms, including this supplement, in their entirety and fully understand and accept all provisions of the Plan and the Terms.
In addition, by accepting the benefits under this grant, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the “Nature of Grant” section of the Terms, in which the following is clearly described and established: (i) your participation in the Plan does not constitute an acquired right; (ii) the Plan and your participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) your participation in the Plan is voluntary; and (iv) the Company and its subsidiaries, affiliates and joint ventures are not responsible for any decrease in the value of the shares of common stock underlying your RSU Award.
Notifications
Securities Law Information
Any RSUs offered under the Plan and the shares of common stock underlying the RSUs have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan and any other document relating to any RSU Award may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and its subsidiaries, affiliates and joint ventures and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present Employees of the Company or one of its subsidiaries, affiliates and joint ventures, made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
|
|||||
Netherlands |
There are no country-specific provisions.
|
||||
Norway
|
Notifications
Exchange Control Information
In general, you should not be subject to any foreign exchange requirements in connection with the acquisition or sale of shares of common stock under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If the transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.
Foreign Asset / Account Reporting Information
You may be subject to foreign asset reporting as part of your ordinary tax return. Norwegian banks, financial institutions, limited companies, etc. must report certain information to the Tax Administration. Such information may then be pre-completed in your tax return. However, if you have traded, or are the owner of, financial instruments (e.g., shares of common stock) not pre-completed in your tax return, you must enter this information in the Form RF-1159, which is an appendix to the tax return.
|
||||
Oman
|
Notifications
Securities Law Information
Offerings under the Plan are addressed only to Eligible Employees of the Company or a subsidiary, affiliate or joint venture of the Company. The Plan, the Terms and any related documents do not constitute the marketing or offering of securities in Oman and consequently, have not been registered or approved by the Central Bank of Oman, the Omani Ministry of Commerce and Industry, the Omani Capital Market Authority or any other authority in the Sultanate of Oman.
|
||||
Panama
|
Notifications
Securities Law Information
Your RSU Award is granted pursuant to the Plan and the shares of common stock which may be issued on the expiration of the Restricted Period are offered in a private transaction. This is not an offer to the public and the offer is not subject to the protections established by Panamanian securities laws, nor registration requirements.
|
||||
Peru |
Notifications
Securities Law Notification
|
Notifications
Foreign Asset / Account Reporting Notification
Romanian residents generally are not required to seek authorization from the National Bank of Romania to participate in the Plan or to open or operate a foreign bank account to receive any proceeds under the Plan. However, if you acquire 10% or more of the registered capital of a non-resident company, you must file a report with the National Bank of Romania (“NBR”) within 30 days from the date such ownership threshold is reached. This is a statutory requirement, but it does not trigger the payment of fees to NBR. You may be required to provide the Romanian bank to which you transfer any proceeds under the Plan with appropriate documentation regarding the source of the income.
|
|||||
Russia
|
Notifications
Securities Law Information
These materials do not constitute advertising or an offering of securities in Russia nor do they constitute placement of the shares of common stock in Russia. The issuance of shares of common stock pursuant to the RSU Award described herein has not and will not be registered in Russia and hence, the shares of common stock described herein may not be admitted or used for offering, placement or public circulation in Russia.
U.S. Transaction and Sale Restrictions
Any shares of common stock issued pursuant to the RSU Award shall be delivered to you through a brokerage account in the U.S. You may hold shares of common stock in your brokerage account in the U.S.; however, in no event will shares of common stock be issued to you and/or share certificates or other instruments be delivered to you in Russia. You are not permitted to make any public advertising or announcements regarding the RSU Award or shares of common stock in Russia, or promote these shares of common stock to other Russian legal entities or individuals, and you are not permitted to sell or otherwise dispose of shares of common stock directly to other Russian legal entities or individuals. You are permitted to sell shares of common stock only on the New York Stock Exchange and only through a U.S. broker.
Exchange Control Notification
As of April 17, 2020, the requirement to repatriate cash proceeds from participation in the Plan (e.g., cash dividends, sale proceeds) back to Russia may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. In other words, you should be able to receive, hold and remit dividends and proceeds from the sale of shares of common stock acquired under the Plan into and out of your brokerage account opened in the U.S. without any requirement to first repatriate such funds to an authorized bank in Russia. You should be aware that the rules related to foreign bank accounts are different and that pursuant to changes effective December 2, 2019 (with retroactive effect to January 1, 2018), certain restrictions with respect to payments by non-residents into a Russian currency resident’s foreign bank account will continue to apply where the foreign bank account is located in the U.S. You should contact your personal advisor to confirm the application of the exchange control restrictions prior to vesting in the RSU Award and selling shares of common stock as significant penalties may apply in case of non-compliance with the exchange control restrictions and because such exchange control restrictions are subject to change.
Foreign Asset/Account Reporting Notification
As of January 1, 2020, Russian residents are required to report the opening, closing or change of details of any foreign brokerage account to the Russian tax authorities within one month of opening, closing or change of details of such account. Russian residents also are required to submit an annual cash flow report for any such foreign brokerage account on or before June 1 of the following year (the first report is due by June 1, 2021 for the year 2020). You should consult with your personal legal advisor to determine the applicability of these reporting requirements to any brokerage account opened in connection with your participation in the Plan.
Anti-Corruption Law
You should be aware that certain individuals who hold public office in Russia, as well as their spouses and dependent children, are prohibited from opening or maintaining foreign brokerage or bank accounts and holding any securities, whether acquired directly or indirectly, in a foreign company (including shares of common stock acquired under the Plan).
|
||||
Serbia | Notifications |
Securities Law Information
The RSU Award is not subject to the regulations concerning public offers and private placements under the Law on Capital Market. As set forth in the Terms, the RSU Award is subject to the laws of the State of New Jersey,
U.S.A. (without regard to its conflict of law provisions).
Foreign Asset/Account Reporting Notification
Residents of Serbia may hold foreign accounts to receive proceeds only upon obtaining prior permission of the National Bank of Serbia (“NBS”). Further, Serbian residents are obligated to provide the foreign account number to the NBS within 30 days of opening such account. Serbian residents must also file an update to the NBS on Form RN on a quarterly basis. Serbian residents are also obligated to transfer any funds received to their Serbian bank account within 30 days of payment. As the exchange control regulations in Serbia may change without notice, you should consult with your personal advisor with respect to all applicable reporting obligations.
|
|||||
Singapore
|
Notifications
Restriction on Sale and Transferability
You hereby agree that any shares of common stock acquired pursuant to the RSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the RSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The RSU Award is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the RSU Award being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or joint venture of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or joint venture in writing when you receive an interest (e.g., RSU Award, shares of common stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or joint venture when you sell shares of the Company’s common stock or any related company (including when you sell shares of common stock acquired upon the expiration of the Restricted Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of .either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.
|
||||
Slovak Republic
|
There are no country-specific provisions.
|
||||
Slovenia |
Terms and Conditions
|
or joint ventures throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or joint ventures over and above the specific terms of the Plan on an ongoing basis. Consequently, you understand that any RSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or joint ventures) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary RSU Award since the future value of the RSU Awards and shares of common stock is unknown and unpredictable. In addition, you understand that the RSU Award would not be made to you but for the assumptions and conditions referred to above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any RSU Award shall be null and void.
You also understand and agree that, as a condition of the grant of the RSU Award, the termination of your employment for any reason (including the reasons listed below), the RSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or joint ventures (unless otherwise specifically provided in the Terms). In particular, you understand and agree that the RSU Award will be forfeited without entitlement to the underlying shares of common stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Restricted Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to “despido improcedente”), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985.
Notifications
Exchange Control Notification
To participate in the Plan, residents of Spain must comply with exchange control regulations in Spain. The acquisition, ownership and disposition of shares of the Company’s common stock must be declared for statistical purposes to the Spanish Dirección General de Comercio e Inversiones (the “DGCI”) , which is a department of the Ministry of Economy and Competitiveness. In addition, you must declare ownership of any shares of common stock to the DGCI each January while the shares of common stock are owned. The sale of shares of common stock must also be declared to the DGCI in January after the year in which the sale occurred, unless the sale proceeds exceed the applicable threshold (currently €1,502,530), in which case, the filing is due within one month after the sale.
Further, you are required to electronically declare to the Bank of Spain any foreign accounts (including brokerage accounts held abroad), as well as securities (including shares of common stock acquired under the Plan) held in such accounts, if the value of the transactions for all such accounts during the prior year or the balances in such accounts (including any payments of cash or shares of common stock made to you pursuant to the Plan) together with the value of such instruments as of December 31, or the volume of transactions with non-Spanish residents during the prior or current year, exceed €1,000,000. Generally, you will be required to report on an annual basis.
Foreign Asset/Account Reporting Notification
You may be subject to a tax reporting obligation if you hold assets and/or have bank accounts outside of Spain. If the value of the assets, including shares of common stock, dividends, dividend equivalents, or the bank accounts outside of Spain exceeds €50,000 (as determined separately for assets and for bank accounts) as of December 31 of the relevant tax year, you will be required to report the assets and/or bank accounts on your annual tax return for such year (or at any time during the year in which you dispose of such right or asset). After the assets and/or bank accounts are initially reported, you will be subject to the reporting obligations only if the value of any previously-reported assets or accounts increases by more than €20,000. The reporting must be completed by March 31 each year.
You should consult with your personal tax and legal advisors to ensure compliance with your personal reporting obligations.
Securities Law Information
No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the RSU Award. The Plan and the Terms have not been nor will
|
they be registered with the Comisión Nacional del Mercado de Valores, and do not constitute a public offering prospectus.
|
|||||
Sweden
|
Terms and Conditions Authorization to Withhold
The following provision supplements the “Tax Withholding” section of your Terms:
Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the “Tax Withholding” section of the Terms, in accepting the RSU Award, you authorize the Company and/or the Employer to withhold shares of common stock or to sell shares of common stock otherwise deliverable to you upon vesting/settlement to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.
|
||||
Switzerland
|
Notifications
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
Foreign Asset / Account Reporting Information
You are required to declare all of your foreign bank and brokerage accounts in which you hold cash or securities, including the accounts that were opened and/or closed during the tax year, as well as any other assets, on an annual basis on in your tax return. This includes RSU Awards granted to you under the Plan which should not be subject to the net wealth tax, but must be reflected “pro memoria” in the statement on bank accounts and securities (Wertschriftenverzeichnis) that you are required to file with your tax return.
|
||||
Taiwan
|
Notifications
Securities Law Information
The RSU Award and the shares of common stock to be issued pursuant to the Plan are available only to Eligible Employees of the Company and its subsidiaries, affiliates and joint ventures. The grant of the RSU Award and offer of participation in the Plan does not constitute a public offer of securities by a Taiwanese company.
Exchange Control Notification
You may acquire and remit foreign currency (including proceeds from the sale of shares of common stock or the receipt of any dividends or dividend equivalents) through an authorized foreign exchange bank, into Taiwan, up to US$5,000,000 per year without justification. Remittance of funds related to the sale of shares of common stock should be made through an authorized foreign exchange bank. If the transaction amount is TWD$500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.
|
||||
Thailand
|
Notifications
Exchange Control Notification
In the event that the amount of the proceeds from the sale of shares of common stock or the receipt of dividends or dividend equivalents acquired under the Plan is US$1,000,000 or more in a single transaction, you will be required to repatriate such proceeds into Thailand after you receive them and to convert the funds into Thai Baht or deposit the proceeds in a foreign currency deposit account maintained by a bank in Thailand within 360 days. In this case, you will be required to provide information associated with the source of such income on the Foreign Exchange Transaction Form to the authorized agent for reporting to an exchange control officer.
|
||||
Turkey |
Notifications
Securities Law Information
|
Under Turkish law, you are not permitted to sell shares of the Company’s common stock in Turkey; instead, the sale must take place outside Turkey, which will be the case if the shares of common stock are sold on the New York Stock Exchange on which the shares are currently listed.
You may be required to engage a Turkish financial intermediary to assist with the sale of shares of common stock acquired under the Plan. While you should not need to engage a Turkish financial intermediary with respect to the acquisition of such shares of common stock (as no consideration is paid for the RSU Awards or underlying shares of common stock), this is less certain. In light of this uncertainty, you should consult your personal legal advisor prior to the expiration of the Restricted Period or any sale of shares of common stock to ensure compliance with the financial intermediary requirements.
|
|||||
Ukraine
|
Terms and Conditions Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of common stock at vesting, less any Tax-Related
Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of common stock and to force the immediate sale of such shares of common stock depending on the development of applicable exchange control laws and regulations.
|
||||
United Arab Emirates
|
Notifications
Securities Law Information
The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and joint ventures and is in the nature of an “exempt personal offer” of equity incentives to Eligible Employees of the Company’s subsidiary in the United Arab Emirates. The Plan, the Terms and any other grant documents you may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person. Prospective recipients of the securities offered (i.e., shares of the Company’s common stock) should conduct their own due diligence on the securities. If you do not understand the contents of the Plan and the Terms, you should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan. The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on your Employer’s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.
|
United Kingdom
|
Terms and Conditions Tax Acknowledgment
You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by Her Majesty’s Revenue and Customs (“HRMC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.
Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the “Tax
Withholding” section of the Terms.
|
||||
Vietnam
|
Terms and Conditions Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of common stock at vesting, less any Tax-Related Items and
broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of common stock and to force the immediate sale of such shares of common stock depending on the development of applicable exchange control laws and regulations.
|
Din tildeling modner på de(t) tidspunkt(er), der fremgår af Morgan Stanleys aktieplanssystem (Morgan Stanley Stock Plan System), medmindre den modner eller ophører på et tidligere tidspunkt af de grunde, der er beskrevet i Vilkårene. På modningstidspunktet konverteres din Tildeling til et tilsvarende antal ordinære aktier i Selskabet.
|
Your Award shall vest on the date(s) reflected in the Morgan Stanley Stock Plan System, unless vested or terminated earlier for the reasons set forth in the Terms. Your Award shall be converted into an equivalent number of Company shares of common stock upon vesting of the Award.
|
||||
4. Udnyttelseskurs
Der skal ikke betales nogen udnyttelseskurs i forbindelse med modning af din Tildeling eller Selskabets udstedelse af ordinære aktier til dig i overensstemmelse med den ovenfor beskrevne modningstidsplan.
|
4. Exercise price
No exercise price is payable upon the vesting of your Award or the issuance of shares of the Company’s common stock to you in accordance with the vesting schedule described above.
|
||||
5. Din retsstilling i forbindelse med fratræden
Ved din fratræden vil din Tildeling blive behandlet i overensstemmelse med bestemmelsen "Ansættelsesforholdets ophør" (defineret som Termination of Employment i Vilkårene), hvilken bestemmelse er opsummeret umiddelbart nedenfor.
–Frivillig fratræden, Misligholdelse eller Opsigelse af Berettiget Årsag. Hvis dit ansættelsesforhold inden for den Betingede Periode (defineret som Restricted Period i Vilkårene) ophører som følge af din egen opsigelse eller opsiges som følge af din forsætlige eller grove misligholdelse eller som følge af anden Berettiget Årsag (defineret som Cause i Vilkårene), fortaber du retten til din Tildeling (og eventuelt optjent udbyttemodværdi) på tidspunktet for ophøret af dit ansættelsesforhold.
–Salg. Hvis dit ansættelsesforhold inden for den Betingede Periode ophører, og Selskabet vurderer, at ophøret skyldes et salg af dit datterselskab, afdeling eller joint venture, vil følgende del af din Tildeling og eventuelt optjent udbyttemodværdi blive udbetalt til dig på det tidspunkt, hvor sådan udbetaling ville være sket, hvis dit ansættelsesforhold ikke var ophørt: En tredjedel, hvis ansættelsesforholdet ophører på eller efter Tildelingstidspunktet, men før 1-årsdagen for Tildelingen (resten fortaber du retten til på tidspunktet for ophøret af dit ansættelsesforhold); og hele Tildelingen, hvis ansættelsesforholdet ophører på eller efter 1-årsdagen for Tildelingen.
–Ufrivilligt ophør, der ikke skyldes dårlig performance, en Berettiget Årsag, pensionering, dødsfald eller invaliditet. Hvis Selskabet vurderer, at dit ansættelsesforhold er ophørt ufrivilligt inden for
den Betingede Periode, uden at det skyldes dårlig performance, en Berettiget Årsag, pensionering,
|
5. Your rights upon termination of employment
The treatment of your Award upon termination of employment will be determined in accordance with the “Termination of Employment” section of the Terms summarized immediately below.
–Voluntary Termination, Misconduct or Termination for Cause. If your employment is voluntarily terminated or your employment is terminated as a result of your deliberate, willful or gross misconduct or for Cause (as defined in the Terms) during the Restricted Period (as defined in the Terms), your Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends.
–Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof (the remainder will be forfeited on the date your employment ends); and all if employment terminates on or after the first anniversary of the Grant Date.
–Involuntary Termination Not for Poor Performance, or Without Cause, Retirement, Death or Disability. If the Company determines that your employment is involuntarily terminated during the Restricted Period not for poor performance, or without Cause, retirement, death or disability but on or after the first anniversary, a pro rata portion of your unvested Award and accrued dividend equivalents will be
distributed to you at such time as they would have been paid if your employment had continued. The pro
|
Performance Level
|
Percentile Rank
|
Payout %
|
||||||
Maximum |
80th percentile and above
|
200%
|
||||||
Target |
55th percentile
|
100%
|
||||||
Threshold |
30th percentile
|
50%
|
||||||
Below Threshold
|
Below 30th percentile
|
0%
|
If primary reason your employment
ends is due to:
|
Here’s what happens to your Performance Share Units (PSUs):
|
||||
Voluntary Termination
|
If the Grantee’s employment ends after the Award Period has ended but prior to the payout date, the PSU Award and accrued dividend equivalents will be distributed to the Grantee at such time as they would have been paid if the Grantee’s employment had continued, based on actual performance during the Award Period as determined in accordance with Section III.
For the avoidance of doubt, if the Grantee’s employment ends during the Award Period, the PSU Award and accrued dividend equivalents will be forfeited on the date the Grantee’s employment ends.
|
||||
Misconduct
Termination for poor performance or for Cause
|
Notwithstanding if the Award Period has ended, if the Grantee’s employment ends prior to the payout date, this PSU Award and accrued dividend equivalents will be forfeited on the date the Grantee’s employment ends.
|
||||
Involuntary Termination (not for poor performance)
Retirement Death Disability
|
A pro rata portion of the unvested PSU Award and accrued dividend equivalents (based on the number of completed months held during the Award Period prior to the date employment terminated) will be distributed to the Grantee at such time as they would have been paid if the Grantee’s employment had continued, based on actual performance during the Award Period as determined in accordance with Section III. The remainder will be forfeited on the date the Grantee’s employment ends.
The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Employer or the Company or any subsidiary, affiliate, or JV of the Company, and the denominator of which is the total number of months during the Award Period.1
|
||||
Sale (for example, sale of your subsidiary, division or JV)
|
The following portion of this PSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if the Grantee’s employment had continued, based on actual performance during the Award Period as determined in accordance with Section III:
•one-third if employment terminates on or after the Grant Date but before the first anniversary thereof (the remainder will be forfeited on the date the Grantee’s employment ends); and
•all if employment terminates on or after the first anniversary of the Grant Date.
|
||||
Change in Control of the Company
|
If there is a Change in Control during the first year of the Award Period, the PSU Award will be converted to a Restricted Stock Unit award at 100% of target and become payable on the scheduled vesting date subject to the Grantee’s continuous employment.
If there is a Change in Control after the first year of the Award Period , the PSU Award will be converted to a Restricted Stock Unit award based on actual relative TSR through the Change in Control date using the Change In Control stock price as the ending price for Organon and become payable on the scheduled vesting date subject to the Grantee’s continuous employment.
|
In the event of an involuntary termination without Cause before the second anniversary after the closing of a Change in Control, the unvested Restricted Stock Unit award (which was converted from the PSU Award at the time of the Change in Control) shall become fully payable on the scheduled vesting date.
If the surviving, successor or acquiring company does not assume the unvested award or substitute similar awards, the Grantee’s award will generally vest and settle prior to the effective time of such Change in Control, as provided in Section 25(b) of the Organon ISP.
|
Country |
Additional Terms and Conditions, and notifications
|
||||
The People’s
Republic of China
|
Terms and Conditions Payment of Award
Any PSU Award granted to Grantee will be settled in cash only. This means that upon settlement of Grantee’s PSU Award, Grantee will receive in cash the value of the underlying shares of common stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to Grantee via local payroll.
|
||||
Netherlands |
There are no country-specific provisions.
|
||||
Singapore
|
Notifications
Restriction on Sale and Transferability
Grantee hereby agrees that any shares of common stock acquired pursuant to the Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The PSU Award is being granted to Grantee pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to Grantee with a view of the PSU Award being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If Grantee is a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or joint venture of the Company, Grantee is subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or joint venture in writing when Grantee receives an interest (e.g., PSUs, shares of common stock) in the Company or any related companies. In addition, Grantee must notify the Singaporean subsidiary, affiliate or joint venture when Grantee sells shares of the Company’s common stock or any related company (including when Grantee sells shares of common stock acquired upon the expiration of the Restricted Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of Grantee’s interests in the Company or any related company within two days of .either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.
|
||||
Switzerland
|
Notifications
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be
publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing
|
body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
Foreign Asset / Account Reporting Information
Grantee is required to declare all of Grantee’s foreign bank and brokerage accounts in which Grantee holds cash or securities, including the accounts that were opened and/or closed during the tax year, as well as any other assets, on an annual basis on in Grantee’s tax return. This includes Awards granted to Grantee under the Plan which should not be subject to the net wealth tax, but must be reflected “pro memoria” in the statement on bank accounts and securities (Wertschriftenverzeichnis) that Grantee is required to file with Grantee’s tax return.
|
|||||
United Arab Emirates
|
Notifications
Securities Law Information
The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and joint ventures and is in the nature of an “exempt personal offer” of equity incentives to Eligible Employees of the Company’s subsidiary in the United Arab Emirates. The Plan, the Terms and any other grant documents Grantee may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person. Prospective recipients of the securities offered (i.e., shares of the Company’s common stock) should conduct their own due diligence on the securities. If Grantee does not understand the contents of the Plan and the Terms, Grantee should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan. The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on Grantee’s Employer’s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.
|
If primary reason your employment
ends is due to:
|
Here’s what happens to your Stock Options:
|
||||
Voluntary Termination
Termination for poor performance or for Cause
|
Any unvested stock options will be forfeited on the date your employment ends.
Any stock options that are already vested will expire at the earlier of 3 months from the date your employment ends and the original Expiration Date.
|
||||
Misconduct |
Any stock options (unvested and vested) will be forfeited on the date your employment ends.
|
||||
Involuntary Termination (not for poor performance)
Retirement
|
A prorated portion of your unvested stock options will vest and become exercisable on the scheduled Vesting Date(s). The prorated portion will equal the full amount of this stock option award (whether vested or unvested) times the number of completed months during the Restricted Period and prior to the date employment ends, divided by the total number of months during the Restricted Period of the grant1, reduced by the number of stock options that have vested. The remaining unvested portion will be forfeited on the date your employment ends.
The portion of your stock options that are already vested and/or vests in accordance with the above will expire at the earlier of the day before the one-year anniversary of the date your employment ends and the original Expiration Date.
|
||||
Death Disability
|
A prorated portion of your unvested stock options will vest and become exercisable on the scheduled Vesting Date(s). The prorated portion will equal the full amount of this stock option award (whether vested or unvested) times the number of completed months during the Restricted Period and prior to the date employment ends, divided by the total number of months during the Restricted Period of the grant1, reduced by
the number of stock options that have vested. The remaining unvested portion will be forfeited on the date your employment ends.
|
Country |
Additional Terms and Conditions, and notifications
|
||||
Netherlands |
There are no country-specific provisions.
|
||||
Singapore
|
Notifications
Restriction on Sale and Transferability
You hereby agree that any shares of common stock acquired pursuant to the stock option will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the stock option, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The stock option is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the stock option being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or joint venture of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or joint venture in writing when you receive an interest (e.g., stock options, shares of common stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or joint venture when you sell shares of the Company’s common stock or any related company (including when you sell shares of common stock acquired upon the expiration of the Restricted Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of .either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.
|
||||
Switzerland
|
Notifications
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
Foreign Asset / Account Reporting Information
You are required to declare all of your foreign bank and brokerage accounts in which you hold cash or securities, including the accounts that were opened and/or closed during the tax year, as well as any other assets, on an
annual basis on in your tax return. This includes stock options granted to you under the Plan which should not be
|
subject to the net wealth tax, but must be reflected “pro memoria” in the statement on bank accounts and securities (Wertschriftenverzeichnis) that you are required to file with your tax return.
|
|||||
United Arab Emirates
|
Notifications
Securities Law Information
The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and joint ventures and is in the nature of an “exempt personal offer” of equity incentives to Eligible Employees of the Company’s subsidiary in the United Arab Emirates. The Plan, the Terms and any other grant documents you may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person. Prospective recipients of the securities offered (i.e., shares of the Company’s common stock) should conduct their own due diligence on the securities. If you do not understand the contents of the Plan and the Terms, you should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan. The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on your Employer’s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.
|
By | /s/ Kevin Ali | ||||
Kevin Ali | |||||
Chief Executive Officer |
By | /s/ Matthew Walsh | ||||
Matthew Walsh | |||||
Chief Financial Officer |
November 12, 2021
|
/s/ Kevin Ali | ||||
Kevin Ali | |||||
Chief Executive Officer |
Dated: November 12, 2021
|
/s/ Matthew Walsh | ||||
Matthew Walsh | |||||
Chief Financial Officer |